Results 251 to 260 of about 5,464,915 (400)
Targeting of PTP4A3 overexpression sensitises HGSOC cells towards chemotherapeutic drugs
In HGSOC with normal KRAS expression, high PTP4A3 expression regulates autophagy activation. Conversely, in HGSOC with high KRAS expression, KRAS dictates autophagy control, and PTP4A3 is not required. When high PTP4A3 expression is inhibited, HGSOC cells are preferentially sensitised towards DNA‐damaging agents.
Ana López‐Garza+3 more
wiley +1 more source
A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.
E. Ratner+20 more
semanticscholar +1 more source
Genetic marker: a genome mapping tool to decode genetic diversity of livestock animals. [PDF]
Panchariya DC+9 more
europepmc +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
Utilizing Short Interspersed Nuclear Element as a Genetic Marker for Pre-Harvest Sprouting in Wheat. [PDF]
Kandpal P+6 more
europepmc +1 more source
The first genetic characterization of Setaria marshalli (Nematoda, Spirurida) with reliable DNA barcoding based on a mitochondrial genetic marker. [PDF]
Kitajima C, Ichijo T, Ichikawa-Seki M.
europepmc +1 more source
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
Marginal interaction test for detecting interactions between genetic marker sets and environment in genome-wide studies. [PDF]
Shen L+7 more
europepmc +1 more source
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham+21 more
wiley +1 more source